Early Results: Zanubrutinib-Sonrotoclax-Obinutuzumab for CLL
August 11, 2026
In an early-stage clinical trial, zanubrutinib-sonrotoclax-obinutuzumab was well tolerated and all patients with CLL / SLL responded to treatment.
In an early-stage clinical trial, zanubrutinib-sonrotoclax-obinutuzumab was well tolerated and all patients with CLL / SLL responded to treatment.
Delaying the addition of obinutuzumab to acalabrutinib-venetoclax to the second yearby one year significantly reduced the risk of infections in patients with CLL.
Sonrotoclax plus obinutuzumab appears to be well-tolerated and produces deep responses in patients with treatment-naïve CLL / SLL
After patients with CLL were treated with venetoclax-obinutuzumab, their immune systems gradually recovered, but this was slower in patients with deep responses.
Though it is still early, the combination of pirtobrutinib-venetoclax-obinutuzumab appears to have good efficacy in patients with Richter transformation.
First-line treatment with combination pirtobrutinib, venetoclax, and obinutuzumab produces deep remissions in patients with CLL.
Adding early Obinutuzumab to Acalabrutinib-Venetoclax significantly increases rates of uMRD in the bone marrow of patients with treatment-naïve CLL.
Combination ibrutinib-venetoclax-obinutuzumab provided short-term control for patients with Richter’s transformation, but responses were not durable.
Atezolizumab-venetoclax-obinutuzumab produced high remission rates, but immune-related side effects limit its usefulness as a frontline CLL therapy.